Abstract 4529
Background
First line therapies usually induce the longest progression free survival (PFS) in advanced/metastatic cancer as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and progression free survival (PFS). We have studied TGR and PFS before and after participation in phase I IT trials.
Methods
We retrospectively studied 173 patients who were enrolled in Phase I IT trials at our institution between January 2012 and September 2017. Patients should have received at least one line of CCT before and after IT. Baseline characteristics (sex, age, tumor type, presence of liver disease, number of CCT lines prior to IT, type of CCT and IT) were recorded. PFS before and after IT was calculated. A ratio of PFS after/before IT (PFSaftIT /PFSbefIT) over 1.2 was considered clinically significant. TGR was calculated based on the formulas: TGR = 100 (exp(TG)−1), TG = 3 Log(Dt/D0)/t.
Results
37 patients met inclusion criteria. Baseline characteristics are shown in the table. Nine of 37 patients (6 CRC, 3 renal cancer) presented a PFSaftIT/PFSbefIT rate over 1.2. Regarding TGR, of 16 patients in whom TGRpre and TGRpost were available, 3 patients (2 CRC, 1 NSCLC) presented a decrease in TGR greater than 15% when given treatment after IT therapy.Table: 1228P
| Characteristics | N = 37 |
| Female | 17 |
| Median (M) age at diagnosis (range) | 55 (31-79) |
| M lines prior to IT (range) | 2 (1-5) |
| Primary tumor Gastrointestinal Genitourinary Gynecological NSCLC Head and neck Breast cancer | 19 7 5 4 1 1 |
| Presence of liver disease (pre/IT/pro) | 15/18/31 |
| CCT class (pre/post IT) Platinum derivatives Other alkylating agents (a) Antimetabolites a Anthracyclines Topoisomerase inhibitors (i) Antimicrotubules a Antiangiogenic a Signal transduction i Immunotherapy Others | 14/18 0/3 14/21 3/0 13/7 5/4 17/19 1/3 4/1 4/3 |
| Combined/monotherapy during IT | 22/15 |
Conclusions
Our data suggest a better outcome on ensuing systemic therapies after IT. Further prospective investigations are needed to select the subset of patients who are more prone to a re-sensitization to CCT and to understand the mechanisms underlying.
Clinical trial identification
Legal entity responsible for the study
Clínica Universidad de Navarra.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
I. Melero: Advisory: BMS, Roche, AstraZeneca, Genmab, Alligator, Tusk, Bioncotech, Merck/Serono. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract